Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study
2025; Thieme Medical Publishers (Germany); Volume: 79; Issue: S 01 Linguagem: Inglês
10.1055/s-0045-1804649
ISSN1438-8790
AutoresMarcel Wiesweg, Shirish M. Gadgeel, Byoung Chul Cho, Lu Shen, Enriqueta Felip, Hidetoshi Hayashi, Alexander I. Spira, Benjamin Besse, Michael Thomas, Scott Owen, Yongsoo Kim, Soo‐Youn Lee, Joana Mourão, Youngkwan Lee, Yanqiu Zhao, Yifeng Fang, Nicolas Girard, Zhe Liu, Ping Sun, S. M. P. Oliveira, Hong Shen, Luis Paz‐Ares, Shin Matsumoto, Hiroshi Tanaka, Abrar Ahmad, Т. Андабеков, Patrapim Sunpaweravong, Özgür Özyılkan, James Chih‐Hsin Yang, Maya Gottfried, O. Hernandez, Martin Kimmich, Diego Cortinovis, Diego Kaen, Lydia Montes, S Popat, Thomas Newsom-Davis, David R. Spigel, Jia Xie, Tao Sun, E. Fennema, M. Daksh, Marguerite Ennis, Sean K. Sethi, Joshua Bauml, Duc Nguyen,
Tópico(s)Gastric Cancer Management and Outcomes
Referência(s)